Prof. Dr. Raimar Loebenberg Receives Leadership Award from the Canadian Society for Pharmaceutical Sciences

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / June 27, 2022 /XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) ("XPhyto" or the "Company") is pleased to congratulate Prof. Dr. Raimar Loebenberg as the 2022 recipient of the CSPS Award of Leadership in Canadian Pharmaceutical Sciences. Dr. Loebenberg is a Professor in the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta ("UoA"), the founder and director of the Drug Development and Innovation Centre (DDIC), UoA, and is a director and founder of XPhyto since 2018.

The CSPS Award of Leadership in Canadian Pharmaceutical Sciences is bestowed upon an individual who has demonstrated leadership in advancing the cause of pharmaceutical research and development in Canada. Prof. Dr. Loebenberg received a Bachelor of Science degree in Pharmacy from the Johannes Gutenberg-University, Mainz, Germany and a PhD in Pharmaceutics from the Johann Wolfgang Goethe-University, Frankfurt, Germany. He joined the University of Alberta in 2000 where he is the founder and director of the Drug Development and Innovation Centre, Faculty of Pharmacy and Pharmaceutical Sciences. Prof. Dr. Loebenberg's research interests are in biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases such as lung cancer, tuberculosis and leishmanasis. He is a cofounder of RS Therapeutics Inc., a foam-based topical drug delivery company.

Prof. Dr. Loebenberg's recent notable positions include: president of the Canadian Society for Pharmaceutical Sciences 2014 to 2015; vice chair of the United States Pharmacopeia Dietary Supplement Expert Committee 2016 to 2017; current member of the United States Pharmacopeia Dietary Supplement Expert Committee; current vice chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science; and current member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology and the Scientific Advisory Panel on Opioid Analgesic Abuse.

XPhyto is proud to have Prof. Dr. Loebenberg on its board of directors and leading its psychedelic medicine program with a multi-pronged approach including GMP drug synthesis, proprietary drug delivery systems, novel psychedelic analogue engineering, and clinical validation.

About XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and manufacture, standardization, and evaluation of psychedelic compounds for the treatment of neurological conditions. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

XPhyto Therapeutics Corp.

Hugh Rogers, CEO and Director
Email: info@xphyto.com
Phone: +1 780-818-6422

Forward looking statements

This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company's goal of building a successful diagnostic, drug delivery, and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not succeed in developing a commercial product; that the sale of products may not be a viable business; that the Company may be unable to scale its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; currency risks; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: XPhyto Therapeutics Corp.